XENON PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Dawn Svoronos

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dawn Svoronos”): 66,244,095 for, 3,593,715 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 25,556,685 for, 71,365 against.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Elizabeth Garofalo

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elizabeth Garofalo”): 68,942,869 for, 894,941 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 25,618,454 for, 9,596 against.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gary Patou

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gary Patou”): 68,936,669 for, 901,141 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 25,618,454 for, 9,596 against.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gillian Cannon

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gillian Cannon”): 68,942,319 for, 895,491 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 25,618,454 for, 9,596 against.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Ian Mortimer

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ian Mortimer”): 69,082,169 for, 755,641 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 25,618,454 for, 9,596 against.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Justin Gover

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Justin Gover”): 68,866,647 for, 971,163 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 25,618,454 for, 9,596 against.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Patrick Machado

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick Machado”): 64,129,706 for, 5,708,104 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 23,550,634 for, 2,077,416 against.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Steven Gannon

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Steven Gannon”): 69,048,114 for, 789,696 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were elected as directors to serve until the 2026 annual meeting of shareholders or until their respective successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 25,618,454 for, 9,596 against.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Corporation's named executive officers;

XENON PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay")”): 67,252,200 for, 2,125,675 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, on an advisory basis, was approved as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 63 managers: 25,492,269 for, 133,511 against, 9,596 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 162 managers: 59,019,274 for, 1,430,136 against, 447,650 abstained, 129,634 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To appoint PricewaterhouseCoopers LLP ("PwC") as the Corporation's auditor to hold office until the next annual meeting of the Corporation;

The 61 asset managers below reported 25,558,144 for, 9,596 withheld, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

Description as filed by funds: To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditors of the Corporation;

XENON PHARMACEUTICALS INC.’s own tally for this item (“4. Remuneration of Auditor”): 72,040,092 for, 24,835 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The authority of the audit committee of the Board to set the remuneration of the auditor for the ensuing year was approved as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 25,558,144 for, 0 against, 9,596 abstained.

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.